Study identifier:NIS-GKR-DUM-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Prevalence of EED and quality of life evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD patients
Gastroesophageal Reflux Disease
-
No
-
All
2000
Observational
20 Years - 80 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to asses the EED symptom prevalence in Koran GERD patients with typical reflux symptom and to evaluate quality of life with the scales including Gerd Q.
Location
Location
Seoul, Kyungkido, Republic of Korea
Location
Seoul, Kyungkido, Republic of Korea
Location
Sungnam, Kyungkido, Republic of Korea
Location
Suwon, Kyungkido, Republic of Korea
Location
Cheonan, Chungnam, Republic of Korea
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.